Literature DB >> 16337665

In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda.

Halidou Tinto1, Claude Rwagacondo, Corinne Karema, Denise Mupfasoni, Waltruda Vandoren, Emmanuel Rusanganwa, Annette Erhart, Chantal Van Overmeir, Eric Van Marck, Umberto D'Alessandro.   

Abstract

Plasmodium falciparum in-vitro susceptibility to chloroquine (CQ), monodesethylamodiaquine, quinine and dihydroartemisinin was investigated in Rwandan patients with a parasitaemia of at least >or=4000/microl. The study was carried out in November-December 2003. Dihydroartemisinin was the most potent (GM IC(50)=2.6nmol/l, 95% CI 2.2-3.2) among the drugs tested. Resistance to chloroquine was 45% (33/74) and that to monodesethylamodiaquine 7% (5/74). All the tested isolates were susceptible to quinine. The mean IC(50) of monodesethylamodiaquine, quinine and dihydroartemisinin was significantly higher for chloroquine-resistant than for chloroquine-sensitive strains (P<0.05). The IC(50) of each drug was significantly and positively correlated to that of the other three drugs (P<0.005), and this correlation was higher between CQ and monodesethylamodiaquine (r=0.8). In-vitro CQ resistance is linked to that of the other drugs tested. Most worrying is the positive correlation between the IC(50) of dihydroartemisinin and the other drugs, more particularly with CQ, suggesting an increased tolerance of the parasites to all drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16337665     DOI: 10.1016/j.trstmh.2005.09.018

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  16 in total

1.  Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda.

Authors:  Frederick N Baliraine; Samuel L Nsobya; Jane Achan; James K Tibenderana; Ambrose O Talisuna; Bryan Greenhouse; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Côte d'Ivoire).

Authors:  W Yavo; K B Bla; A J Djaman; S B Assi; L K Basco; A Mazabraud; M Koné
Journal:  Afr Health Sci       Date:  2010-06       Impact factor: 0.927

3.  In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.

Authors:  John Okombo; Steven M Kiara; Josea Rono; Leah Mwai; Lewa Pole; Eric Ohuma; Steffen Borrmann; Lynette Isabella Ochola; Alexis Nzila
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

4.  Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda.

Authors:  Fatima Nawaz; Samuel L Nsobya; Moses Kiggundu; Moses Joloba; Philip J Rosenthal
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

5.  In silico comparative genome analysis of malaria parasite Plasmodium falciparum and Plasmodium vivax chromosome 4.

Authors:  Atefeh Taherian Fard; Amna Salman; Bahram Kazemi; Habib Bokhari
Journal:  Parasitol Res       Date:  2009-01-29       Impact factor: 2.289

6.  Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites.

Authors:  Paul Hunt; Axel Martinelli; Katarzyna Modrzynska; Sofia Borges; Alison Creasey; Louise Rodrigues; Dario Beraldi; Laurence Loewe; Richard Fawcett; Sujai Kumar; Marian Thomson; Urmi Trivedi; Thomas D Otto; Arnab Pain; Mark Blaxter; Pedro Cravo
Journal:  BMC Genomics       Date:  2010-09-16       Impact factor: 3.969

7.  Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial.

Authors:  Jane Achan; James K Tibenderana; Daniel Kyabayinze; Fred Wabwire Mangen; Moses R Kamya; Grant Dorsey; Umberto D'Alessandro; Philip J Rosenthal; Ambrose O Talisuna
Journal:  BMJ       Date:  2009-07-21

8.  Artemisinin resistance in rodent malaria--mutation in the AP2 adaptor μ-chain suggests involvement of endocytosis and membrane protein trafficking.

Authors:  Gisela Henriques; Axel Martinelli; Louise Rodrigues; Katarzyna Modrzynska; Richard Fawcett; Douglas R Houston; Sofia T Borges; Umberto d'Alessandro; Halidou Tinto; Corine Karema; Paul Hunt; Pedro Cravo
Journal:  Malar J       Date:  2013-04-05       Impact factor: 2.979

9.  Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.

Authors:  Adoke Yeka; James Tibenderana; Jane Achan; Umberto D'Alessandro; Ambrose O Talisuna
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

10.  Anti-plasmodial action of de novo-designed, cationic, lysine-branched, amphipathic, helical peptides.

Authors:  Naveen K Kaushik; Jyotsna Sharma; Dinkar Sahal
Journal:  Malar J       Date:  2012-08-01       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.